United States: Chancery Court Dismisses Breach Of Contract Claim Due To Plaintiff's Failure To Proffer A Reasonable Construction Of Merger Agreement Provision

Last Updated: September 28 2017
Article by Christopher H. Cunningham and Joseph Phelps

In Fortis Advisors LLC v. Shire US Holdings, Inc., No. 12147-VCS (Del. Ch. Aug. 9, 2017), the plaintiff, Fortis Advisors LLC, which was acting as representative (the "Representative") for the former stockholders of SARcode Bioscience Inc., a private biopharmaceutical company (the "Target"), pursuant to a merger agreement, alleged that the acquiror Shire US Holdings, Inc., a Delaware subsidiary of a global biopharmaceutical company (the "Acquiror"), breached the provisions of a merger agreement by refusing to pay certain milestone payments that were due.  The Court of Chancery granted the Acquiror's motion to dismiss for failure to state a breach of contract claim, concluding that, while the Acquiror's interpretation of the operative provision at issue was reasonable based on its plain and unambiguous language, the Representative failed to proffer a competing reasonable construction of such provision and thus the Court was required to grant the motion to dismiss.

The parties entered into the merger agreement, dated as of March 23, 2013, while the Target was developing and seeking regulatory approval for a drug, Lifitegrast, that showed promise to treat the signs (e.g., staining or tear break-up time, as based on objective signs identified by an eye-care professional) and symptoms (e.g., eye dryness or discomfort, as subjectively reported by patients) of dry eye disease. The consideration payable under the merger agreement consisted of certain fixed up-front payments and subsequent contingent payments that depended on the Acquiror's ability to move the drug through clinical trials and regulatory approvals.  The Representative alleged that two of the contingent milestones had been achieved and the Acquiror was obligated to make $425 million in milestone payments to former Target stockholders.  The Acquiror denied that the two milestone payments had been met and indeed insisted that they would never be met.

Prior to execution of the merger agreement, the Target conducted a Phase II clinical trial and a Phase III clinical trial (referred to as "OPUS-1") that successfully established the efficacy and safety of Lifitegrast in reducing the signs of dry eye disease. A second Phase III clinical trial (referred to as "OPUS-2") was designed and initiated in late 2012, and had two co-primary efficacy endpoints specified in the so-called OPUS-2 Study Protocol:  the sign endpoint (designed to evaluate the drug's efficacy in treating the signs of dry eye disease) and the symptom endpoint (designed to evaluate the drug's efficacy in treating the symptoms of dry eye disease).  Under the OPUS-2 Study Protocol, the results for the endpoints required statistical significance.

The Representative alleged that, under the merger agreement, the former Target stockholders were entitled to two contingent payments triggered by the occurrence of the "OPUS-2 Study Endpoint Achievement Date" (the "Achievement Date"): one payment is referred to as the OPUS-2 Successful Completion Milestone and the other is referred to as the Base Case Approval Milestone.  The Achievement Date was defined in the merger agreement as occurring:

upon receipt by or on behalf of [Acquiror]...of audited final tables, figures and listings from the OPUS-2 Study (x) that demonstrate both components of the co-primary efficacy endpoints of the OPUS-2 Study as specified in the OPUS-2 Study Protocol have been achieved and (y) which do not, in a significant and clinically meaningful respect, result a materially less favorable safety/tolerability profile..., taken as a whole, for the Product than for corresponding data generated for the Product in the OPUS-1 Study, which less favorable safety/tolerability profile would reasonably be expected to significantly reduce anticipated Product Sales....

If the Achievement Date had been achieved, then the former Target stockholders would be entitled to receive the two payments at issue pursuant to the following terms of the merger agreement:

  • OPUS-2 Successful Completion Milestone. "Within ten (10) business days following the [Achievement Date] (the "OPUS-2 Successful Completion Milestone"), [Acquiror] shall notify the [Representative] that the OPUS-2 Successful Completion Milestone has been satisfied and shall, within twenty (20) business days following the date of achievement of the OPUS-2 Successful Completion Milestone, pay...$175,000,000 (such amount, the 'OPUS-2 Successful Completion Milestone Payment')"; and
  • Base Case Approval Milestone. "Within ten (10) business days following receipt by or under the authority of [Acquiror]...of the first Regulatory Approval in the United States for a Product for the Covered Indication with the co-primary Sign and Symptom specified in the OPUS-2 Study Protocol included in the 'Indications and Usages' section of the label of the Product (the 'Base Case Approval Milestone'), [Acquiror] shall notify the [Representative] that the Base Case Approval Milestone has been satisfied and shall, within twenty (20) business days following the date of achievement of the Base Case Approval Milestone, pay...$250,000,000 (such amount, the 'Base Case Approval Milestone Payment')...."

Upon completion of the OPUS-2 Study in November 2013, the Acquiror informed the Representative that the OPUS-2 Study achieved the symptom endpoint but failed to achieve the sign endpoint.  The Acquiror designed and initiated an additional Phase III clinical trial (the "OPUS-3 Study") in November 2014 and, in early 2015, the Acquiror filed a New Drug Application (an "NDA") with the Food and Drug Administration (the "FDA"), which included evidence from the OPUS-2, OPUS-1 and other previous trials; the FDA declined to approve Lifitegrast based on the data submitted in the NDA.

Apparently believing the Achievement Date had occurred, the Representative wrote the Acquiror to ask whether it intended to make the OPUS-2 Successful Completion Milestone Payment. The Acquiror responded, stating that none of the milestones at issue had been met, or would ever be met, since the Achievement Date had not occurred because the OPUS-2 Study failed to meet the sign endpoint.

In February 2016, the Acquiror refiled its NDA with the FDA, which included additional OPUS-3 Study data, and it was approved. After the FDA approved the label relating to the drug and the Acquiror posted it on its website, the Representative alleged that the former Target stockholders were also due the Base Case Approval Milestone Payment, due to the regulatory approval, in addition to the OPUS-2 Successful Completion Milestone Payment.

As a threshold matter, the Court noted that questions regarding contract interpretation can be answered as a matter of law on a motion to dismiss only "[w]hen the language of a contract is plain and unambiguous." Dismissal of a contract dispute under Rule 12(b)(6) is proper "only if the defendants' interpretation is the only reasonable construction as a matter of law."

The Acquiror contended that the merger agreement was unambiguous and required that both the sign and symptom endpoints be achieved in a statistically significant manner in the OPUS-2 Study and, because the OPUS-2 Study did not achieve the sign endpoint, the Achievement Date had not occurred and will never occur. In supporting its argument, the Acquiror pointed to language in the definition of Achievement Date (the occurrence of which is a threshold requirement for both payments at issue), which is defined to occur "upon receipt...of audited final tables, figures and listings from the OPUS-2 Study...that demonstrate that both components of the co-primary efficacy endpoints of the OPUS-2 Study as specified in the OPUS-2 Study Protocol have been achieved" (emphasis added).

The Representative argued that the Achievement Date was achieved because clinical data used in determining whether the sign and symptom endpoints have been met are not limited to OPUS-2 Study data (where the symptom endpoint was achieved), but can incorporate prior clinical trials (where, in OPUS-1, the sign endpoint was achieved). In particular, the Representative made three principal arguments:

  • the definition of Achievement Date did not expressly exclude data from any clinical trials other than the OPUS-2 Study;
  • the definition of Achievement Date requires that a Phase III clinical trial need only be conducted "in accordance with" the OPUS-2 Study Protocol, which means conducted "in a way that agrees with or follows" it, but need not be identical; and
  • once the FDA approved the drug label, the Representative was able to confirm that, contrary to the Acquiror's representations, the OPUS-2 Study did in fact irrefutably achieve both endpoints.

After considering the Representative's proposed construction, the Court found it "unreasonable." With respect to the first point, the Court noted that the definition of Achievement Date "unambiguously reflects an intent that only [data from the OPUS-2 Study] should be considered when assessing whether the sign and symptom co-primary efficacy endpoints had been achieved" and that the Representative's construction would require the insertion of additional text into the definition of Achievement Date.

The Court found the second point similarly unpersuasive, noting, among other things, that (i) the OPUS-2 Study was defined as a clinical trial "to be conducted" and thus the OPUS-1 Study did not fit within the temporal requirements in the definition and (ii) OPUS-1 and OPUS-2 studies were conducted pursuant to separately defined protocols and thus the OPUS-1 Study was not conducted "in accordance with" the OPUS-2 Study Protocol.

Finally, with respect to the Representative's third argument, that approval of the FDA label for the drug provided irrefutable proof that the OPUS-2 Study achieved both endpoints, the Court noted that this ignored that the OPUS-2 Study Protocol specifically required that the study data achieve statistical significance in order for the OPUS-2 Study to achieve both endpoints, and the Representative did not plead that the label in question actually showed the required statistical significance.

As a result, the Court concluded that the Representative's construction of the merger agreement was unreasonable, while the Acquiror's construction was reasonable based on a clear an unambiguous reading of the contract, and granted the motion to dismiss for contract breach.

Fortis Advisors LLC v. Shire US Holdings Inc., C.A. No. 12147-VCS (Del. Ch. Aug. 9, 2017)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions